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Abstract
The classical form of a1-antitrypsin deficiency (ATD) is associated with hepatic fibrosis and hepatocellular carcinoma. It is
caused by the proteotoxic effect of a mutant secretory protein that aberrantly accumulates in the endoplasmic reticulum of
liver cells. Recently we developed a model of this deficiency in C. Elegans and adapted it for high-content drug screening
using an automated, image-based array scanning. Screening of the Library of Pharmacologically Active Compounds
identified fluphenazine (Flu) among several other compounds as a drug which reduced intracellular accumulation of mutant
a1-antitrypsin Z (ATZ). Because it is representative of the phenothiazine drug class that appears to have autophagy
enhancer properties in addition to mood stabilizing activity, and can be relatively easily re-purposed, we further
investigated its effects on mutant ATZ. The results indicate that Flu reverses the phenotypic effects of ATZ accumulation in
the C. elegans model of ATD at doses which increase the number of autophagosomes in vivo. Furthermore, in nanomolar
concentrations, Flu enhances the rate of intracellular degradation of ATZ and reduces the cellular ATZ load in mammalian
cell line models. In the PiZ mouse model Flu reduces the accumulation of ATZ in the liver and mediates a decrease in
hepatic fibrosis. These results show that Flu can reduce the proteotoxicity of ATZ accumulation in vivo and, because it has
been used safely in humans, this drug can be moved rapidly into trials for liver disease due to ATD. The results also provide
further validation for drug discovery using C. elegans models that can be adapted to high-content drug screening platforms
and used together with mammalian cell line and animal models.
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Introduction
Alpha-1-antitrypsin deficiency (ATD) has long been recognized
as a genetic cause of liver disease in children. Recently it has
become apparent that liver disease due to ATD may be even more
significant in the adult population. The United Network of Organ
Sharing reports ,90–100 liver transplant procedures per year for
ATD with 85–90% being done in adults (UNOS data, 2012,
personal communication).
The liver disease of ATD is characterized by mostly fibrosis/
cirrhosis with relatively mild inflammation and steatosis and it
predisposes to hepatocellular carcinoma [1,2]. The vast majority
of these cases are caused by the classical form of ATD,
homozygous for the ATZ allele. This allele bears a mis-sense
mutation that is associated with misfolding and a tendency for the
mutant polypeptide to polymerize and aggregate [3]. The mutant
ATZ protein accumulates in the endoplasmic reticulum (ER) of
hepatocytes, leading to cellular dysfunction by gain-of-toxic
function mechanisms [3].
We have investigated the mechanisms by which accumulation
of mutant ATZ in the ER is counteracted by endogenous protein
degradation machinery and have found that the proteasomal and
autophagic degradative systems both participate [4]. Retrograde
translocation as a part of the ERAD pathway, ubiquitination and
ultimately the proteasome probably participate in the degradation
of soluble forms of ATZ in the ER at low levels of expression [4–
6]. The autophagic system appears to play an important role in
degradation of insoluble polymers/aggregates and perhaps also
contributes to the fate of soluble forms of ATZ [5,7,and 8].
Autophagy appears to be particularly important when there are
high levels of expression in model systems [8]. As shown by studies
using the PiZ x GFP-LC3 mouse model of ATD, autophagy is
specifically activated when ATZ expression leads to accumulation
in the ER of liver cells in vivo [7]. There is also long-standing
evidence for non-autophagic, non-proteasomal mechanisms con-
tributing to intracellular degradation of ATZ, including a sortilin-
mediated Golgi-to-lysosome pathway [9], and other as yet
uncharacterized pathways are likely to be involved as well.
Because autophagy appears to play a key role in intracellular
disposal of insoluble ATZ and because it is specifically activated
when ATZ accumulates in the ER, we recently hypothesized that
drugs which enhance the autophagic pathway could reduce the
hepatocellular load of mutant ATZ and therein ameliorate its
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major proteotoxic sequella, hepatic fibrosis, in ATD. We found
that a commonly used anticonvulsant and mood stabilizer,
carbamazepine (CBZ), enhanced autophagic disposal of ATZ,
reduced hepatic load of ATZ and hepatic fibrosis in the PiZ mouse
model of ATD [10]. In a novel C. elegans model of ATD that
robustly recapitulates the human disease, high-content screening
of a relatively simple drug library discovered 3 drugs which reduce
the cellular and organismal load of ATZ and also have potent
autophagy enhancer activity [11]. Together, these findings provide
powerful evidence for the concept that drugs which enhance
proteostasis mechanisms, in this case autophagy, represent
attractive candidates for chemoprophylaxis of liver disease in
ATD.
One of the drugs that was identified by unbiased screening of
the LOPAC drug library using the C. elegans model of ATD,
fluphenazine, is a mood stabilizer that has been used safely in
humans for many years. Here we show that it has potent
autophagy enhancer activity and reduces the cellular load of ATZ
in the C. elegans model, in mammalian cell line models and in the
PiZ mouse model of ATD. Most importantly this drug also reduces
hepatic fibrosis in the PiZ mouse. The study therefore provides a
basis for considering clinical trials of this drug for patients with
severe liver disease due to ATD.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC; permit number: 1009948) of the University
of Pittsburgh. Surgery was performed under isoflurane anesthesia,
and all efforts were made to minimize suffering.
Materials
Rabbit anti-human AT antibody was purchased from DAKO
(Santa Barbara, CA) and goat anti-human AT from Diasorin
(Stillwater, MN). Antibody to GAPDH was purchased from US
Biochemical. Living ColorsHA.v. antibody was purchased from
Clontech (Mountain View, CA). Antibody to LC3 was purchased
from Novus Biologicals (Littleton, CO). Antibody to p62 was
purchased from Cell Signaling Technology (Danvers, MA).
Fluphenazine was purchased from Sigma and prepared as a stock
solution of 5 mg/ml DMSO. Carbamazepine (CBZ) was pur-
chased from Sigma and prepared in a stock solution of 25 mg/ml
DMSO. Doxycycline was purchased from Sigma and prepared
1mg/ml in water. Flu and CBZ in sustained release pellets were
manufactured by Innovative Research of American (Sarasota, FL).
Cell Lines
The human epidermal HeLa cell line with doxycycline-
regulated expression of ATZ (HTO/Z) has been described
previously [12]. HTO/M, HTO/Saar and HTO/SaarZ are
HeLa cell lines with doxycycline-regulated expression of wild type
AT, AT Saar variant, and AT Saar Z variant respectively [12].
The CHOK1-Z cell line with stable constitutive expression of
ATZ in Chinese hamster ovary cells has been previously described
[13].
The HG2TONBZ#2 and HG2TONGZT#1 cell lines are
derived from the human hepatoma cell line HepG2. The parent
HepG2 cell line was engineered in each case for inducible (Tet-
On) expression of ATZ-fluorophore chimeric proteins. For the
HG2TONBZ#2 line the fluorophore CFP was engineered in-
frame at the carboxyl terminus of ATZ. Expression of ATZ-CFP
cannot be detected in the absence of doxycycline (dox) and
increases profoundly within 6 hours when dox is added and the
cellular properties of ATZ-CFP appear to recapitulate what is seen
for ATZ in other genetically engineered cell lines. This includes
alterations in the kinetics of secretion by pulse-chase analysis and
accumulation in the insoluble fraction whereas a chimeric protein
with CFP engineered at the carboxyl terminus of the nonpoly-
merogenic variant AT Saar does not appear at all in the insoluble
fraction of cellular homogenates (K Covella, P Hale, DH
Perlmutter, unpublished).
For the HG2TONGZT #1 cell line the fluorophore is GFP and
engineered in frame at the amino terminus of the ATZ. Expression
of ATZ is not detected in the absence of doxycycline (dox) but is
induced and increases markedly in time- and dose-dependent
fashion when dox is added. This cell line also recapitulates the
know properties of ATZ, including intracellular accumulation and
formation of insoluble polymers/aggregates, in contrast to 2
different HG2TONGMT cell lines with Tet-On inducible
expression of wild type AT with GFP engineered into the amino
terminus of wild type AT (K Covella, P Hale, DH Perlmutter,
unpublished).
For experiments with Flu, the Tet-off inducible cell lines were
cultured in the absence of doxycycline for at least 6 days to ensure
expression of AT. The Tet-on inducible cell lines were cultured in
the presence of doxycycline 200 ng/ml for 3 days for optimal
expression. The cells were then subcultured into separate
monolayers in fresh complete growth medium and incubated for
48 hours in the absence or presence of Flu or CBZ. Flu or CBZ
was added to the growth medium. The duration of incubation
with Flu was determined to be optimal at 48 hours based on
experiments in which the duration was varied from 24 to 72 hours.
Doses of Flu were initially based on previous studies of its effects in
cell lines [14,15]. After the incubation cells were homogenized and
cell homogenates separated into insoluble and soluble fractions
according to our previously established technique [13]. Samples of
10 mgs each were subjected to immunoblot analysis for AT and
GAPDH.
Transgenic Mice
PiZ mice that have been bred into the FVB/N background have
been described previously [10]. Sections of liver tissue were stained
with hematoxylin and eosin, PAS, PAS after diastase treatment,
TUNEL, and Sirius Red using standard techniques [17,18].
Sections of liver tissue were also stained with goat anti-human AT
followed by donkey anti-goat Cy3 to detect AT-containing
intracellular globules. The number of AT-containing globules
was quantified blindly by counting cells in 6 microscopic fields of
10 different sections for each liver. The number of nuclei, as
determined by Hoechst staining, was used to exclude the
possibility that different numbers of cells were counted in liver
sections from mice treated with Flu or CBZ as compared to
controls. Sirius Red staining was also quantified by blindly
analyzing 6 microscopic fields of 10 different sections for each
liver using percent area stained red as determined by ImageJ
software [10]. For quantification of TUNEL staining only cells
with positive staining over the entire cell body were counted. The
number of TUNEL+ hepatocytes per high power field (,250 cells
per high power field) was counted in 6 fields of 10 different sections
for each liver. Hepatic hydroxyproline concentration was assayed
as previously described (10).
For experiments involving drug administration in mice in vivo,
doses of 1–10 mg/kg/day for Flu was based on previous studies of
its biological effects in mice [14,15]. The duration of 3 weeks was
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based on our experimental series with CBZ [10]. Flu and CBZ was
delivered by oral gavage or slow-release subcutaneous pellets
formulated by Innovative Research of America. Control mice
were given DMSO by gavage or placebo pellets specifically
designed for each of these drugs.
Radioimmunoprecipitation, SDS-PAGE and Immunoblot
Analysis
Biosynthetic labeling, pulse-chase labeling, immunoprecipita-
tion and SDS-PAGE/fluorography for AT followed previously
published protocols [12]. Radioactivity measured in TCA
precipitates, using previous methods [10], did not show any effects
of Flu on total protein synthesis or secretion (data not shown). For
the pulse labeling experiments, HTO/Z cells were incubated for
48 hours in the absence or presence of Flu in several different
concentrations and then subjected to labeling for 30 mins. The cell
lysates were then examined by immunoprecipitation and the
immunoprecipitates analyzed by SDS-PAGE/fluorography. For
the pulse-chase experiments, HTO/Z cells were incubated for 48
hours in the absence of presence of Flu 0.1 nM and then pulse
labeled for 60 mins. The cells were then washed and incubated in
growth medium without tracer for several different time intervals
to constitute the chase. Flu was included during the pulse and
chase periods. The extracellular fluid and cell lysate samples were
subjected to immunoprecipitation and the immunoprecipitates
analyzed by SDS- PAGE/fluorography. All fluorograms were
subjected to densitometry. The relative densitometric value of T0
is set at 100% and the remainder of the data set expressed as % of
this control. The data are shown as mean +/2 SD and the mean
value at each time point is shown at the bottom of the figure.
For immunoblot analysis to detect AT or GAPDH, cells were
lysed in 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, pH 8.0.
Protein levels were quantified using the BCA protein assay (Pierce
Biotechnology, Rockford, IL). 10 mg samples were loaded onto
10% precast gels. PVDF membranes were blocked in TBS, 0.5%
Tween 20 (TBST), 5% milk and then incubated with primary
antibody in 5% milk TBST solution. Horseradish peroxidase anti-
goat Ig or anti-mouse Ig (Jackson Labs, Bar Harbor, ME) were
used as secondary antibodies in TBST. Blots were visualized with
Super Signal West Dura or West Femto from Pierce. For
immunoblot on liver, the liver was snap frozen in liquid nitrogen
and stored at280uC. Liver was homogenized in 50 mM Tris-HCl
pH 8.0, 150mM NaCl, 2 mM KCl, 2 mM MgCl2, 0.5% Triton
X-100, 0.5% deoxycholic acid containing 0.1 mM phenylmethyl-
sulfonic acid and complete protease inhibitor cocktail from Roche.
Total protein concentration was measured by BCA assay (Pierce).
Soluble and insoluble fractions were separated by centrifugation
(14,000 rpm, 10 min, 4uC). The insoluble pellet was washed twice
in 50 mM Tris-HCl (pH7.4, 150 mM NaCl) and resuspended in
50 mM Tris-HCl (pH6.8, 5% SDS, 10% glycerol). Equal amounts
of total protein (1 ug) were loaded on 8% SDS-PAGE. After
transfer to PVDF membrane, the blots were blocked in PBS-
Tween20 containing 5% non-fat milk for 1 hr at RT, then goat-
anti human AT antiserum (Diasorin, 1:2500) was applied followed
by three washes. Donkey anti-goat IgG-HRP (Santa Cruz,
1:1,000,000) and West Dura (Pierce) was used for detection of
AT. Anti-living color antibody was used to detect ATZ-CFP
chimeric protein. The blots were also subjected to staining for
GAPDH which is only in the soluble fraction to determine
whether the soluble and insoluble fractions were separated
appropriately and that loading was equivalent for the samples
from the soluble fractions. This involved stripping (Pierce) and
after the blocking step anti-mouse GAPDH (US Biologicals,
1:10,000) and rabbit anti-mouse IgG-HRP (Jackson Labs, 1:5000)
were used to detect GAPDH. The blots were also stained with
GelCode Blue (Pierce) so that loading of insoluble fractions could
be assessed. Quantification was carried out by densitometric
analysis using the ratio of ATZ to GAPDH for the soluble fractions
and of ATZ to GelCode Blue-stained bands in the insoluble
fraction.
Samples of 60 mgs each were subjected to immunoblot analysis
for LC3 (16% precast gel) and p62 (10% gel) in mouse liver whole
cell lysates [19]. Rabbit anti-LC3 (Novus, 1:500) or rabbit anti-p62
(Cell Signaling, 1:1000) was applied as primary antibody, anti-
rabbit Ig (Jackson Labs, 1:50,000) was used as secondary antibody
in TBST.
For ELISA on mouse serum specimens, we first coated Nunc
Maxisorp plates with goat anti-human AT (Bethyl), then blocked
in PBS-Tween20 containing 5% nonfat milk. Serum samples were
loaded into the wells in 1:20,000 dilutions using purified human
AT serial dilutions (1.56 to 100 ng/ml) as a standard. Rabbit-anti
human AT (Dako) was used as capturing antibody, and goat anti-
rabbit IgG-HRP (Dako) as secondary antibody. Protein levels were
detected with OPD (Sigma).
Real Time Quantitative PCR
Total RNA was extracted from PiZ mouse livers with TRIZOL
(Life Technologies, Grand Island, NY). First strand cDNA (RT
reaction) was synthesized from 2 mg of RNA using high capacity
RNA-to-cDNA kit (Applied Biosystems, Foster City, CA) accord-
ing to the manufacturer’s directions. A negative control was
performed without enzyme (NRT reaction). RT and NRT
reactions were also performed on 2 mg of commercially prepared
liver RNA (Ambion, Austin, TX) to serve as the calibrator for the
real time QPCRs. Each experimental sample was normalized to a
nontransgenic control (fold change). For PCR, duplicate aliquots
of the RT reaction and 1 aliquot of the NRT reaction served as
templates for the target genes and the control gene b-glucuron-
idase (GusB). The probes and primers were obtained from Applied
Biosystems (SERPINA1 assay ID: Hs01097800-m1; mouse GusB
assay ID: Mm00446953-m1; human GusB assay ID: Hs9999908-
m1). Real time reactions were run on an ABI7300 using the
following cycling parameters: 95uC for 12 min, followed by 40
cycles of 95uC for 15 s and 60uC for 1 min. Differential gene
expression was calculated by the DDCT calculation [16] The
DDCT method controls for potential differences in efficiency of the
RT, as well as the PCR, whereas calculations based on standard
curves do not (DDCT=DCT(exp) - DCT(ctr) when
DCT=DCT(gene) - DCT(norm)).
C. elegans Strains and Culture Conditions
C. elegans strains, N2, VK1882 (vkIs1882[nhx-2p::sGFP::ATZ;myo-
2p::mCherry]) and VK1093 (vkEx1093[nhx-2p::mCherry::lgg-1]) were
routinely cultured at 20uC on nematode growth medium (NGM)
plates seeded with E. coli strain, OP50. Longevity experiments
were performed NGM agar plates supplemented with DMSO or
Flu to a final concentration of 50 mM. Kaplan-Meier curves were
plotted and median survival times were calculated using PrismH,
GraphPad.
Imaging of Transgenic Animals using ArrayScan VTI
Quantitative analysis of animals expressing fluorescent trans-
genes was performed using the ArrayScan VTI HCS Reader
(Cellomics, ThermoFisher, Pittsburgh, PA, USA) fitted with a 2.5x
objective and a 0.63x coupler as previously described [11]. Briefly,
35 L4 stage animals were placed into wells of 384-well plates
containing DMSO or Flu to a final concentration of 50 mM.
Worms were sorted using the COPAS Biosort to ensure that only
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animals of the similar age and fluorescence intensities were used
for the experiment. Following incubation at 20uC for 24 hours,
sodium azide was added to a final concentration of 50 mM to
anesthetize the animals. Animals were then imaged on the
ArrayScan VTI (Thermo Scientific) and protein aggregates were
quantified using the SpotDetector BioApplication (Thermo
Scientific).
Quantification of mCherry::LGG-1 Puncta
For microscopic image acquisition, approximately 12 worms
were transferred to a 35 mm MatTek glass bottom culture dish
(MatTek, Ashland, MA) containing 6 ml of 50 mM sodium azide.
Confocal images were collected using a Leica TCS SP8
microscope and visualized, rendered and analyzed using Volocity
Software (v6.11, Perkin Elmer). LGG-1 puncta were quantified
using the Threshold Object Identification method in Volocity.
Statistical Analysis
Students t-test was used for most comparisons but the Welch
modified t-test was used to compare experimental groups that
were not paired and did not assume equal variances. Kinetic and
dose-response curves were analyzed by two-way ANOVA with the
Bonferroni post-test using the Prism software application.
Results
Fluphenazine Mitigates the Proteotoxic Effects of ATZ
Accumulation in vivo using the C. elegans Model
In a previous study we used a high-content small molecule
screen of the C. elegans model and identified Flu as a drug which
reduced accumulation of ATZ [11]. Here we sought to determine
whether Flu also mitigates the proteotoxic effect of ATZ
accumulation in this model. We used longevity because our
studies have shown that ATZ expression specifically reduces
longevity in C. elegans [SCP, GAS, DHP, unpublished]. A dose of
50 mM Flu was found to be ideal for longevity experiments. To
ensure that this dose reduces ATZ accumulation we incubated
animals for 24 hours with Flu 50 mM or DMSO in the same
volume added to their feed. sGFP::ATZ accumulation was
monitored by GFP fluorescence using the Arrayscan VTi, as
previously described [11]. Flu mediated a reduction of GFP
intensity that was close to 3-fold, p,0.001 (Figure 1A–E). To
determine whether this dose enhances autophagy we carried out
the same experiment using transgenic C. elegans expressing
mCherry::LGG-1 (LC3)chimeric protein which labels autophago-
somes with red fluorescence. The results show that LGG-1-positive
puncta are significantly elevated (p,0.01 in the animals treated
with Flu (Figure 1F–J). The increase in autophagosomes reached a
magnitude of almost 2-fold, p,0.01 (Figure 1F Although the
increase in LGG-1-positive puncta could be attributed to either
activation of autophagy or decreased autophagosome clearance
due to a block in autophagosome-lysosome fusion, the latter is
unlikely because we have observed completely different results
when C. Elegans is treated with Flu as compared to when
autophagosome-lysosome fusion is inhibited in C. elegans by Rab
7 RNAi. In the former there is increased LGG-1-positive puncta
and decreased ATZ levels (Fig 1A–J) whereas in the latter there
are increased ATZ levels (data not shown).
To determine the effects of Flu on longevity, transgenic animals
expressing sGFP::ATZ were incubated with 50 mM Flu or DMSO
throughout their lifetime. In three separate experiments Flu was
found to increase median survival time by an average of 25 hours
(Table 1 and Figure 1K). This increase in longevity was significant
(p,0.001), especially since the common laboratory strain only
lives ,20 days. Interestingly, this increase in survival was not
observed when N2 control animals were treated with Flu
indicating that Flu does not cause a general improvement in
lifespan (Figure S1). Taken together, these data indicate that Flu
mitigates at least one of the proteotoxic effects of ATZ
accumulation in vivo at doses that reduce ATZ accumulation and
increase autophagosomes.
Fluphenazine Reduces the Cellular Load of ATZ in
Mammalian Cell Line Models of ATD
The HTO/Z cell line was incubated for 48 hours in the absence
or presence of CBZ or Flu and then the cells were homogenized
for analysis of the cell homogenates by immunoblot (Fig 2). The
results show that Flu reduces the steady state levels of ATZ in
insoluble and soluble fractions (Fig 2A). However, the effect is
significantly more potent on insoluble than soluble ATZ levels. It is
first apparent at 0.1 nM. Indeed, the effect of Flu on insoluble
ATZ is greater in magnitude and at lower doses than the effect of
CBZ. Levels of GAPDH show that the differences in the soluble
fraction are not due to loading and demonstrate the integrity of
separating soluble from insoluble fractions of cell homogenate.
Densitometric analysis of multiple experiments shows that the
effect of 0.1 nM Flu on both insoluble and soluble ATZ levels is
statistically significant (Fig 2B). The effect of Flu on ATZ levels in
the HTO/Z cell line is also dose-dependent as shown best by the
densitometric analysis of ATZ levels in Fig 3B. Flu, used at the
same concentrations and time interval, did not affect steady state
levels of wild type AT in the HTO/M cell line (Fig 3B), levels of
mutant AT Saar in the HTO/Saar cell line (Fig 3C) or levels of
mutant AT Saar Z in the HTO/SaarZ cell line (Fig. 3D).
To exclude the possibility that the effect of Flu was peculiar to
the HTO/Z cell line we tested it in several other cell lines. Using 2
new cell lines, HG2TONBZ#2, which has inducible expression of
an ATZ-CFP chimeric protein, and HG2TONGZT#1, a human
hepatoma cell line with inducible expression of a GFP-ATZ
chimeric protein, we found that Flu reduced the cellular load of
ATZ (Fig 4). However, in these cell lines the effect of Flu required
higher doses, 10–100 nM, and the drug had an even lesser effect
on soluble ATZ levels than observed in the HeLa-based HTO/Z
model system. Flu also mediated a reduction in cellular ATZ load
in a CHO cell line with constitutive expression of ATZ (data not
shown). Together these results indicate that the effect of Flu on
intracellular ATZ accumulation is apparent in multiple mamma-
lian cell lines. Elucidation of the mechanism of action will be
necessary to determine why different doses of Flu are required for
effects in the HepG2- compared to the HeLa-based cell line
model.
Effect of Fluphenazine on the Kinetics of Degradation
and Secretion of ATZ in Cell Line Models of ATD
The HTO/Z cell line was subjected to pulse-chase radiolabeling
analysis after incubation for 48 hours in the absence or presence of
Flu 0.1 nM (Fig 5A). The results show that ATZ disappears earlier
in cells treated with Flu as compared to control. Lesser ATZ is
apparent at the later time points of the chase period. There is no
difference in the time of appearance of ATZ in the extracellular
fluid compared treated to untreated cells but lesser amounts of
ATZ are present in EC of treated cells compared to control cells.
These results are most consistent with an effect of the drug that
exclusively increases the rate of intracellular degradation. Quan-
titative analysis by densitometry on multiple experiments (Fig 5B)
shows that there is more rapid disappearance in the presence of
Flu with a half-time for ATZ disappearance of 140 mins in treated
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cells versus 180 mins in control cells (22.2% increase in rate of
degradation, p = 0.0012) and lesser amounts of ATZ in the EC,
especially later in the chase period (120 to 300 mins, p = 0.0033).
Applying a different type of quantitative analysis in which the
amount of AT-specific radioactivity in the IC and EC is combined
at each time point (Fig 5C), the selective effect of Flu on
degradation is evidenced by the reduction in ATZ-specific
radioactivity in Flu-treated cells during the chase.
Figure 1. Effect of Flu treatment on clearance of ATZ and autophagy. Animals expressing sGFP::ATZ were treated with DMSO or 50 mM Flu
for 24 h and GFP intensity measured using the Arrayscan VTI (A). An average of three independent experiments with total n .300 animals per
treatment is shown. Error bars represent SEM. Statistical significance was determined by using a Student’s t-test, ***P,0.001. Representative
Arrayscan images of animals treated with DMSO (B,C) or 50 mM Flu (D,E). Effect of Flu treatment on LGG-1 puncta (F–J). Transgenic animals expressing
mCherry::LGG-1 were treated with DMSO or Flu for 24 h and imaged using a Leica TCS SP8 microscope. LGG-1 puncta was quantified using Threshold
Object Identification method in Volocity (Perkin Elmer, v5.4). Graph shows the average number of LGG-1 puncta in the posterior intestine of the
animal (F). Statistical significance was determined using a Student’s t-test. **P,0.01. Representative confocal images of an mCherry::LGG-1 expressing
animal treated with DMSO (G,H) or 50 mM Flu (I,J). Effect of Flu treatment on longevity of worms (K). The Kaplan-Meier graph showing the average
lifespan of ATZ animals treated with DMSO (blue) or 50 mM Flu (red). Animals treated with 50 mM Flu had significantly (p,0.001) improved lifespan.
Statistical significance was determined using Log-rank (Mantel-Cox) test. Data shown is an average of 3 experiments, n = 150 animals/treatment.
doi:10.1371/journal.pone.0087260.g001
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Fluphenazine Reduces Hepatic ATZ Load and Hepatic
Fibrosis in the PiZ Mouse Model of ATD
Our results indicate that Flu can reduce ATZ load in vivo using
the C. elegans model but here we sought to determine if the drug
can reduce ATZ levels and the major clinical sequella, fibrosis, in
the PiZ mouse model. PiZ mice were treated with Flu 7.5 mg/kg/
day or placebo by daily oral gavage or with sustained release
pellets inserted subcutaneously. In Fig. 6A, the results show
reduced hepatic levels of ATZ in mice treated with Flu. The steady
state levels of insoluble ATZ are significantly reduced by a
magnitude of 2.1-fold (p = 0.021). There was a trend toward lower
levels of soluble ATZ but this trend did not reach statistical
significance. There was no change in human ATZ mRNA levels in
the liver of Flu-treated PiZ mice (data not shown). Most
importantly there was significant reduction in ATZ globules as
determined by PAS/diastase staining, p,0.0001 (Fig 6B) and by
immunofluorescent staining for ATZ (data not shown). Flu also
mediated a significant decrease in fibrosis as determined by Sirius
red staining, p = 0.0105 for Flu (Fig 6C). The reduction in fibrosis
was similar to the effect of CBZ (p= 0.0028). Hepatic hydroxy-
proline content was also significantly reduced by Flu (control
2.557+/20.194 vs. Flu 1.868+/20.186 mg/gm liver tissue,
p = 0.0307). Although there was a trend towards reduced
TUNEL+ hepatocytes in Flu-treated PiZ mice this difference did
not reach statistical significance (p = 0.0741). There was no
additive or synergistic effects of Flu and CBZ administered
together (data not shown). Flu administration had no effect on
serum levels of human AT using ELISA (data not shown). Doses of
Flu below 7.5 mg/kg/day did not reduce ATZ levels, ATZ-
containing globules or fibrosis (data not shown). Flu-treated PiZ
mice had significantly reduced levels of p62 (Figure 6D) and
increased LC3-II:LC3-I ratio (Figure 6E) in the liver compared to
untreated PiZ mice. Together, these data indicate that Flu reduces
hepatic ATZ load and fibrosis and these effects are associated with
increased markers of hepatic autophagy in the PiZ mouse model of
ATD in vivo.
Table 1. Effect of Fluphenazine on median survival times of
sGFP:: ATZ animals.
Experiment DMSO (hrs) FLU50 (hrs)
1 500 526
2 527 551
3 505 530
Average 511 536*
The sGFP::ATZ worm strain was treated with Flu 50 mM or DMSO for
determination of life-span. Results are presented as median survival time
(hours) and were analyzed for statistical significance using Student’s t-test.
*p,0.05.
doi:10.1371/journal.pone.0087260.t001
Figure 2. Effect of Flu on steady state levels of ATZ in genetically engineered HeLa HTO/Z cell line. Separate monolayers were incubated
for 48 hours in the absence or presence of Flu or CBZ. Drug was added to the medium daily. Cells were then harvested, homogenized and the cell
homogenates separated into soluble and insoluble fractions. The fractions were analyzed by immunoblot for AT (top) as well as loading controls,
GelCode Blue (middle) and GAPDH (bottom). A, HTO/Z cell line expressing mutant ATZ; B, Densitometric analysis of 4 separate experiments in HTO/Z
cell line. Mean +/2 standard error is shown with error bars. Asterisks denote a statistically significant difference (p = 0.0029 for insoluble ATZ;
p = 0.0292 for soluble ATZ).
doi:10.1371/journal.pone.0087260.g002
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Figure 3. Effect of Flu on steady state levels of ATZ compared to wild type AT and other AT variants in genetically engineered HeLa
cell lines. Exactly as in Figure 2. A, HTO/Z cell line expressing mutant ATZ; changes in relative ATZ levels as determined by densitometry is shown at
the top of the panel; B, Dose-response relationship for the effect of Flu on soluble and insoluble ATZ levels in the HTO/Z cell line. These data
represent mean +/2 standard error from 4 separate experiments and the effect of dose is highly significant, p,0.0001 by two-way ANOVA; C, HTO/M
cell line expressing wild type AT; D, HTO/Saar cell line expressing mutant AT Saar; E, HTO/Saar Z cell line expressing mutant AT Saar Z. In each case,
GAPDH is used as a loading control for the soluble fraction and GelCode Blue stained bands are used as a loading control for the insoluble fraction.
doi:10.1371/journal.pone.0087260.g003
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Discussion
A series of studies have shown that autophagy plays a critical
role in intracellular disposal of the mutant ATZ molecule that
aberrantly accumulates in liver cells and is responsible for hepatic
proteotoxicity in the classical form of ATD [4]. Furthermore, we
recently found a drug which enhances autophagy, CBZ, can
reduce the hepatic load of ATZ and hepatic fibrosis in the PiZ
mouse model of ATD [10]. In the current study we show that
another drug which has the property of enhancing the autophagic
pathway, Flu, reduces ATZ accumulation in a C. elegans model of
ATD, reduces steady state levels of ATZ in 4 different mammalian
cell line models of ATD and reduces hepatic ATZ accumulation in
the PiZ mouse model of ATD. Most importantly, administration
of this drug to PiZ mice reduces hepatic fibrosis, the most
important toxic sequellae of ATZ accumulation in the liver. Like
CBZ, Flu acts solely on the intracellular degradation of ATZ, with
no apparent effect on synthesis or secretion of this mutant protein
and it has no effect on wild type AT or on nonpolymerogenic AT
variants. In contrast to CBZ which mediates decreases in both
insoluble and soluble ATZ, Flu appears to act more robustly on
insoluble ATZ. One might use this data to conclude that Flu acts
solely on autophagic disposal of ATZ whereas CBZ acts on both
autophagic and non-autophagic mechanisms for disposal of ATZ.
However, it is still not clear how the various forms of ATZ that
accumulate in the ER, including soluble monomers, soluble
polymers and insoluble polymers/aggregates are segregated into
the various pathways for disposal which include autophagic,
proteasomal and non-autophagic, non proteasomal mechanisms.
Several results provide evidence that Flu enhances autophagy
in vivo. In addition to increased LC3 II:I ratio and decreased p62
levels in the liver of the PiZ mouse after Flu administration, Flu
mediated an increase in LGG-1-positive puncta in the C. elegans
model in vivo. Although the latter result could be attributed to an
effect of Flu that led to increased autophagosomes because of
decreased autophagosome-lysosome fusion, we found that inhibi-
tion of autophagosome-lysosome fusion by Rab7 RNAi has effects
that were completely opposite of those of Flu. When C. elegans was
treated with Rab7 RNAi there were increased ATZ levels.
The results of this study provide a validation for the C. Elegans
model of ATD and automated high-content drug screening
platform recently developed using this model [11]. Flu was
originally identified as a potential therapeutic compound by
completely unbiased screening of the LOPAC drug library. The
drug was then shown to have a reproducible dose-dependent effect
on ATZ load and proteotoxicity when moved sequentially from
the C. elegans model to a mammalian cell line and finally to a
transgenic mouse model of ATD. This means that the C. elegans
model/screening platform can be used effectively and robustly to
identify therapeutic drug candidates and furthermore implies the
extraordinary similarity in the cell biology and pharmacology of
ATZ accumulation in worm and mammalian cells. Thus, we
should see major advances in identification of therapeutic drugs
and genetic modifiers of ATD as well as further understanding of
mechanisms by which mutant ATZ elicits proteotoxic effects using
this relatively simple and inexpensive model.
This study also provides further evidence for the application of
drugs with autophagy enhancer activity to therapeutics for ATD.
Previously we found that CBZ enhanced autophagic degradation
of mutant ATZ and that this mechanism led to a reduction in
hepatic fibrosis in the PiZ mouse model of ATD, presumably by
reducing the proteotoxic effects of ATZ accumulation [10].
Subsequently we found that 3 hit compounds from our initial
high-content screen of the C. elegans model have the property of
enhancing autophagy [11]. Because the screening platform is set
up in a way that it could identify drugs which work on cellular
ATZ load by any possible mechanism, including decreased
synthesis, increased secretion or increased degradation by non-
autophagic mechanisms, we suspect that there is something
particularly effective about the autophagy enhancer mechanism
of drug action. In high-throughput screens for drugs which
enhance autophagic degradation of another aggregation-prone
protein, huntingtin, that have been carried out by 2 different
laboratories using different mammalian cell line models [20,21],
drugs in the phenothiazine family have been particularly
prominent among the hit compounds. Indeed, pimozide was a
hit compound in one of these one of these screens [20] as it was in
our screen [11] and the phenothiazine structure was used to
Figure 4. Effect of Flu on steady state levels of ATZ in other genetically engineered cell line models of ATD. Two different cell line
models were analyzed for the effect of Flu exactly as described in Figure 2. A, HG2TONBZ#2; B, HG2TONGZT#1. In each case levels of ATZ and
GAPDH are shown. GelCode blue stained bands are also shown as a control for the insoluble fractions. The change in level of ATZ as determined by
densitometry is shown at the top of the panels.
doi:10.1371/journal.pone.0087260.g004
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Figure 5. Effect of Flu on kinetics of secretion of ATZ in the HTO/Z cell line. Separate monolayers were incubated for 48 hours in the
absence or presence of Flu (0.1 nM) and then were subjected to pulse radiolabeling for 60 mins. The monolayers were rinsed vigorously and then
subjected to chase in medium with excess unlabeled methionine for time periods up to 240 mins. The extracellular fluid (EC) and cell lysates (IC) were
analyzed by immunoprecipitation for AT followed by SDS-PAGE/fluorography. A, Fluorograms of control (top) and Flu-treated cells. Chase time points
are shown at the top. B, Densitometric analysis of kinetics. Disappearance of ATZ from IC compartment is shown on the left and appearance in EC is
shown on the right for n= 3 experiments. Mean +/2SEM is shown for each time point with error bars. The IC disappearance is increased significantly
(p = 0.0012) and the EC appearance is decreased significantly (p = 0.0033), using the matched ANOVA in GraphPad. The half-time for disappearance is
shown with dashed lines, 180 mins for control and 140 mins for Flu-treated cells. C, Densitometric analysis of ATZ fate. Representative fluorographic
images were subjected to densitometric scanning and relative ATZ levels in intracellular and extracellular compartments are shown together for each
time point. The relative densitometric intensity of the ATZ band at T0 IC is set at 100% and every other band is compared to that. The results for
control are shown at left and for Flu on the right. This analysis shows loss of ATZ in the Flu-treated cells that can only be accounted for by increased
degradation.
doi:10.1371/journal.pone.0087260.g005
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Figure 6. Effect of Flu on hepatic ATZ accumulation and hepatic fibrosis in the PiZ mouse model. At 3 months of age a sustained release
pellet containing Flu, CBZ or placebo was inserted subcutaneously into PiZ mice. The pellets contained enough Flu to deliver 7.5 mg/kg/d or CBZ to
deliver 100 mg/kg/day or 200 mg/kg/day on the basis of the average weight of 3-mos old PiZ mice. At the end of 3 weeks, mice were sacrificed and
the liver analyzed by immunoblot for AT (A), PAS/diastase staining (B), Sirius Red staining (C), immunoblot/densitometric analysis for p62 levels (D)
and immunoblot/densitometric analysis for the LC3-II/I ratio (E). The immunoblot in Fig 6A shows ATZ levels at the top and staining with Gel Code
Blue as a control at the bottom. In each case a single sample from the liver of 6 control and 6 Flu-treated PiZ mice is analyzed. The statistical analysis
in panels (B) and (C) was carried out by Image J software determining percent area stained by PAS (B) and Sirius Red (C) in 6 microscopic fields from
10 sections of each liver specimen. The asterisks in panel (C) denote a statistically significant difference, p = 0.0105 for Flu and p=0.0028 for CBZ. The
asterisk in panel (D) denotes a statistically significant different decrease in p62 levels, p = 0.0354 and the asterisk in panel (E) denotes a statistically
significant increase in LC3II/I ratio, p = 0.0075 in the livers of Flu-treated versus control mice (n = 6 each).
doi:10.1371/journal.pone.0087260.g006
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develop a pharmacophore model for virtual screening to identify
additional novel drugs for Huntington’s disease [21]. Flu is also a
member of the phenothiazine drug family with autophagy
enhancer activity and herein is shown to have a putative
therapeutic effect on hepatic fibrosis due to ATD. It is also
important to note that CBZ has structural similarities to the
tricyclic and phenothiazine mood stabilizing drugs. Together,
these observations lead us to conclude that the autophagy
enhancer class of drugs and the phenothiazine structure constitute
excellent leads for further efforts at drug discovery for ATD.
Although it is known that Flu and other members of the
phenothiazine drug family act on dopamine D2 receptors, there is
relatively little known about the effect of these drugs at the
cellular/biochemical level. Older literature mentions effects of Flu
and other phenothiazines on calcium stimulus-response coupling
[22,23], properties that they could hold in common with CBZ and
the autophagic response is known to be regulated by cellular
calcium [24]. It is also worth noting that there is an appealing
teleological basis for the efficacy of drugs which enhance
degradation of cytotoxic proteins as compared to nucleic acid-
based therapeutics currently being considered to target production
of cytotoxic proteins. Drugs which target degradation are acting at
the step most proximal to the proteotoxicity and therefore may not
need to be as effective as drugs which target much earlier steps and
this may be particularly important for ATD because endogenous
AT is produced at such high levels by the liver.
Because Flu is an FDA-approved drug with a well-established
history of safe use, it is a good candidate for clinical trials to reduce
proteotoxicity in ATD. Relatively high doses of Flu were required
for beneficial effects in PiZ mice. The dose of 7.5 mg/kg/day in
mice compares to 2.5–10 mg/day as the initial starting dose in
humans, going up to 40 mg/day (equivalent of ,0.57 mg/kg/day
in a 70 kg man). This difference is very similar to what we
observed for CBZ with doses between 100–200 mg/kg/day
required in mice as compared to 10–20 mg/kg/day used in
humans [10]. It is as yet unclear whether such differences will limit
the effectiveness of these drugs in humans or will be explained by
the known 10- to 20-fold difference in dose of drugs required
because of the high surface area to body weight ratio in rodents
compared to humans. Recently Flu was found to decrease steady
state levels of aggregation-prone prion proteins in cell line and
mouse models [25]. Although autophagy or other degradation
pathways were not investigated, the results could easily be
explained by enhanced autophagic disposal. These observations
therefore provide a basis for further studies of Flu as a potential
therapeutic for ATD as well as other diseases caused by
aggregation-prone proteins.
Supporting Information
Figure S1 Effect of Flu treatment on longevity of N2
controls. As a control for the ATZ longevity on Flu, the lifespan
of N2 animals was assessed upon treatment with DMSO (blue) or
50 mM Flu (red). Animals treated with 50 mM Flu had a modest
but statistically significantly (p,0.05) decrease in lifespan.
Statistical significance was determined using the Logrank (Man-
tel-Cox) test. Data shown is an average of 3 experiments, n = 150
animals/treatment
(TIF)
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